AbbVie Profit Tops Estimates as Arthritis Drug Sales Rise
This article is for subscribers only.
AbbVie Inc. reported first-quarter results that exceeded analysts’ estimates, lifted by sales of its top product Humira, the rheumatoid arthritis treatment.
Profit of 94 cents a share, excluding some items, beat the 85-cent average estimate compiled by Bloomberg. Total revenue rose 10 percent to $5.04 billion, exceeding the $4.98 billion average projection.